Pharma & Biotech Global Week in Review 20 October 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

CAFC denies outsourcing of inventorship to foreign countries: Solvay v. Honeywell (Patents Post-Grant) (IPBiz) (Patently-O)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

WTO paragraph 6 meeting aims at improved use of health waiver (IP Watch)

The absence of investment in new antibiotics (IPBiz)

Integration of intellectual property and regulatory exclusivity strategies for life science companies (IP Spotlight)

Pharmaceutical companies can innovate if they want to (profitability through simplicity)

Medicines Patent Pool seeks business director (IP Watch)

WHO moves IP, innovation out of Director General’s office (IP Watch)

A rights-poor protocol for biodiversity access & benefit-sharing (IP Watch)

EU: When will the “suitable opportunity” arise for changing an obsolete definition? (The SPC Blog)

EU: Paediatric extensions in European countries (The SPC Blog)

Hungary: Interpretation of transitional rules for granting SPC in Hungary (EPLAW)

US: CAFC denies outsourcing of inventorship to foreign countries: Solvay v. Honeywell (Patents Post-Grant) (IPBiz) (Patently-O)

US: ‘At home’ testing for BRCA gene mutations (Patent Docs)

US: New draft guidance for industry: INDs – determining whether human research studies can be conducted without an IND (FDA Law Blog)

US: Patent extensions: some academic perspectives? (The SPC Blog)

US: House lawmakers ask FDA to delay implementation of certain 510(k) changes (FDA Law Blog)

 

Products

Actos (Pioglitazone) – US: Takeda settles Actos patent dispute with Wockhardt (Patent Docs)

Amrix (Cyclobenzaprine) – US: Impax settles Amrix patent suit with Cephalon (Patent Docs)

Copaxone (Glatiramer acetate) – US: Teva fails to obtain advance notice order regarding generic Copaxone (The IP Factor)

Cozaar (Losartan), Hyzaar (Losartan / Hydrochlorothiazide) – US: Mylan receives approvals for generic versions of Hyzaar and Cozaar (SmartBrief)

Erlonat (Erlotinib) – India: Roche v Natco @ Delhi HC – Natco continues arguments (Spicy IP)

Femcon (Norethindrone/Ethinyl estradiol), Loestrin 24 (Norethindrone/Ethinyl estradiol) – US: Para IV – Warner settles patent dispute with Lupin (Patent Circle)

Opana (Oxymorphone) – US: Endo settles patent dispute with Watson over Opana ER (Patent Docs)

Paxil CR (Paroxetine hydrochloride) – US: Mylan to appeal court decision in generic Paroxetine hydrochloride CR case (SmartBrief)

Prevacid (Lansoprazole) – US: Teva announces launch of generic Prevacid SoluTab in United States (SmartBrief)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: